通络方药对糖尿病和肥胖大鼠心肌与主动脉内皮细胞的保护作用及其机制研究
|
摘要
目的:研究通络方药对糖尿病和肥胖大鼠心肌细胞、主动脉内皮细胞功能的保护作用并进一步探讨其机制。方法:以1型糖尿病、2型糖尿病、肥胖SD大鼠为研究对象,运用HE染色、电子显微镜、酶联免疫吸附分析法(ELISA)、免疫组织化学(IHC)、蛋白印迹(Western)和荧光实时定量—逆转录多聚酶链反应(RT-PCR)等多种实验方法,多层次研究高胰岛素血症和糖尿病时氧化应激产生的损伤,黏附分子和前炎症因子骨桥蛋白(OPN)的变化,以及通络方药对OPN的影响和对心肌细胞、主动脉内皮细胞的保护作用,并与抗氧化剂a-硫辛酸及调脂药阿托伐他汀的作用进行对照。结果:1)通络方药对糖尿病和肥胖大鼠氧化应激损伤的影响:①明显升高SOD、GSH、T-AOC、CAT,降低MDA水平。②降低血清CRP水平。③降低肥胖和糖尿病大鼠的血脂水平。④使糖尿病组大鼠NO水平较糖尿病组上升显著,但较正常组低。⑤TLR干预组24h尿蛋白较2型糖尿病组明显降低。2)糖尿病大鼠心肌、主动脉组织结构改变:TLR组较2型糖尿病组大鼠心肌、主动脉组织结构改变明显减轻,但较正常组仍有病理改变。3)TLR组大鼠心肌和主动脉iNOS的mRNA表达及其活性较糖尿病组明显增加。4)TLR干预组OPN表达较肥胖和糖尿病组降低显著,肥胖、2型糖尿病组大鼠心肌PKCβ_2表达较正常组明显增强,TLR干预组大鼠心肌PKCβ_2表达较2型糖尿病组明显减弱,较正常组升高。结论:TLR的干预可以改善糖尿病和肥胖大鼠体内氧化应激系统的紊乱,降低24H尿蛋白、CRP和NO的水平,使大鼠的心肌细胞、主动脉内皮细胞病理结构的改变较糖尿病组明显减轻;还使心肌中PKCβ_2表达下降、血浆中OPN降低及心肌、主动脉OPN表达减弱;通过抑制氧化应激、降低CRP和24H尿蛋白,抑制PKC表达,从而下调OPN的表达,增强iNOS的活性,增加NO合成,可能是通络方药发挥内皮保护功能的机制之一。
Background and objectives:Nowadays obesity and diabetes have become the main diseases that affect human health,and diabetic complications have been the major cause leading to high morbility and mortality of cardiovascular diseases.Dysfunction of endothelial cells attributed to chronic hyperglycemia related oxidative stress is a major factor leading to diabetic macroanglopathy and microanglopathy,and obesity related chronic mild inflammation which leads to insulin resistance is the initial factors contributing to diabetic vascular complications.Osteopontin(OPN) is a multifunctional extracelluar matrix protein and also a kind of cell secretory protein,proinflammation factor and adhesion molecular.It plays a great role in mediating cell aggregation,adhesion, migration,mineralization and reconstruction of bone,immunoregulation,signal transduction and immunity to infectious diseases.Injuries,reparation and remodeling of blood vessles all could stimulate expression of OPN.Hyperglycemia could stimulate expression of OPN in smooth muscle cells.Expression of OPN is up-regulated in smooth muscle cells from diabetic rats and diabetic patients' tunica media of arteries.Oxidative stress induced by hyperglycemia could activate PKC,increase expression of OPN, down-regnlate expression of iNOS,decrease NO,thus affect endothelial functions. Recently OPN has been found to be a pre-inflammation factor.It is highly expressed in fat tissues,could mediate infiltration of macrophage into fat tissue,and is associated with the development of insulin resistance.OPN also has an important role in diabetic anglopathy[4].This study explored the possible mechanisms of Tongluo recipe's protective effects on endothelial functions by observing the pathological changes of myocardium and aorta of obese and experimental diabetic rats,measuring plasma OPN, CRP of obese and experimental diabetic rats and mRNA of iNOS and expression of OPN protein in myocardium and aorta of obese and experimental diabetic rats,so that provide new target and theoretical evidence of diabetic complications.
Materials and methods:We studied the type 1 diabetic rats,obese and experimental type 2 diabetic rats.A number of method including HE dying,electronmicroscope, enzyme-labeled immunosorbent assay,immunohistochemistry,westernblot and RT-PCR were used.The lesions caused by oxidative stress and lipotoxicity,changes of adhere factors and the pre-inflammation factor OPN and the protective effects of TLR on myocardial cells and endothelia of aorta.We also compared the effects of TLR with antioxidants including a-lipoic acid,atorvastatin to further determine the protective effects of TLR and its possible mechanisms.
Results:1) The effects of TLR on oxidative stress of obese and diabetic rats:①Plasma oxidative stress parameters:SOD,GSH,T-AOC,CAT in type 1 diabetic rats significantly reduced compared with normal controls and MDA significantly increased. SOD,GSH,T-AOC,CAT in type 1 diabetes+TLR and type 1DM+ALA increased compared with normal controls,but there were no significant difference.MDA in type 2 diabetic rats was higher than normal controls and SOD significantly reduced.SOD in type 2 diabetes +ALA,type 2 diabetes+TLR were lower than normal controls,but the difference has no significance.MDA in type 2 diabetes +ALA,type 2 diabetes+TLR was lower than DM,but higher than NC.The difference had no significance.②Serum CRP: CRP of obese rats was significantly higher than that of normal controls.CRP of obese+TLR was lower than that of obese rats and the difference was significant.There was no significant difference among obese+atorvastatin,obese+ALA and obese+TLR.CRP of type 2 diabetic rats was significantly higher than that of normal controls.There was no significant difference among type 2 DM+atorvastatin,type 2 DM +ALA and type 2 DM +TLR.CRP of the three groups was lower than that of type 2 diabetic rats;③Changes of blood lipids:TG of obese rats was higher than that of normal controls.TG of obese+TLR increased at the fourth and eighth week,but remained lower than normal controls.At the 12~(th) week it decreased significantly.TG of type 2 diabetic rats was higher than that of normal controls.TG of type 2 DM+TLR reduced from the fourth and it was lower than diabetic rats by the end of the 12~(th) week.The TG of type 2 DM remained higher than normal controls.The TG of type DM+TLR was lower than that of type 2DM+atorvastatin and it reduced significantly compared with that of type 2 DM+AL.TC:At the 4~(th) week TC of obese rats was higher than that of normal controls.TC of obese+TLR also increased at the fourth and eighth week,but remained lower than obese rats.At the 12~(th) week it decreased.TC of type 2 diabetic rats was significantly higher than that of normal controls. The peak appeared at the 4~(th) week and it began to reduce at the 8~(th) and 12~(th) week.TC of type 2 DM+TLR reduced from the fourth and it was lower than diabetic rats by the end of the 12~(th) week.However the TC of type 2 DM remained higher than normal controls.The TC of type DM+atorvastatin reduced more than that of type 2DM+TLR,and the TC of type 2 DM+ALA did not reduce so much as that of type 2 DM+atorvastatin and type 2DM+TLR.HDL:HDL of obese rats was lower than that of normal controls.HDL of obese+TLR was higher than that of obese rats.HDL of type 2 diabetic rats was significantly lower than that of normal controls.TC of type 2 DM+TLR increased significantly compared with diabetic rats,but it was lower than diabetic rats.However the HDL of type 2 DM remained higher than normal controls.There was no significant difference between type 2 DM+TLR and type 2 DM+atorvastatin but the difference between type 2 DM+TLR and type 2 DM+ALA had statistical significance.LDL:LDL of obese rats was higher than that of normal controls.LDL of obese+TLR was higher than that of normal controls but lower than that of obese rats.LDL of type 2 diabetic rats was significantly higher than that of normal controls.The LDL of type 2 DM+TLR was significantly lower than that of type 2 DM,but it was higher than normal controls Reduction of LDL in type 2 DM+TLR was less than that of type 2 DM+atorvastatin but more than type 2 DM+ALA.④iNOS:Serum iNOS of obese rats was lower than that of normal controls.The iNOS of type 2 DM+TLR was significantly higher than that of type 2 DM,but it was still lower than normal controls.There was no significant difference in iNOS between type 2 DM+TLR and type 2 DM+atorvastatin but the difference between type 2 DM+TLR and type 2 DM+ALA had statistical significance;⑤24-hour urine proteins:There was no significant difference on the 24-hour urine proteins between obese rats and normal controls and there also had no statistical difference among obese+TLR, obese+ALA and obese+atorvastatin.24-hour urine proteins of type 2 diabetic rats were significantly higher than those of normal controls.The peak appeared at the 4~(th) week and began to reduce at the 8~(th) and 12~(th) week.24-hour urine proteins of type 2 DM+TLR began to reduce from the 4~(th) week and were significantly lower than those of type 2 diabetic rats at the 8~(th) and 12~(th) week,but remained higher than those of normal controls.The reduction of type 2 DM+atorvastatin was more than that of type 2 DM +TLR,and reduction of type 2 DM +TLR was more than that of type 2 DM+ALA.2)histological changes of myocardia and aorta of diabetic rats:①HE dying:normal myocardia had the morphology of short cylinder.The nucleus was oval-shape and in the middle of the cytoplasma.Myofibrilla could be seen in the cytoplasma.The outline of cell was clear.Mitochondria of diabetic rats were swollen and some of the cristae were broken.Vacuolization could be seen in parts of the mitochondria.The lesions of type 2 DM+TLR were significantly milder than those of type 2 DM.There was no significant difference between type 2 DM+TLR and type 2 DM+atorvastatin.The normal endothelia of intima of aorta pectoralis and smooth cells of tunica media were in regular array and complete.There was no significant difference between obese rats and normal controls.At the 12~(th) week Endothelial cells of diabetic rats were in irregular array and the smooth cells of tunica media proliferated.The lesions of type 2 DM+TLR were significantly milder than those of type 2 DM.There was no significant difference between type 2 DM+ALA and type 2 DM+atorvastatin.②electronmicroscope:In NC,tochondria of myocardial cells were complete.Crista mitochondriales were in parallel array.Myofilament was seen clearly. Myocomma was in good order and intercalary disc was normal.The structures and numbers of mitochondria were normal.At the 12~(th) week myofilament of myocardial cells of type 2 diabetic rats were twisted and the mitochondria were swollen.Some of the cristae were broken.Vacuolization could be seen in parts of the mitochondria.The lesions of type 2 DM+TLR were significantly milder than those of type 2 DM.There was no significant difference between type 2 DM+TLR and type 2 DM+atorvastatin.The normal endothelial cells were thin and flat.The nucleus was fusiform..At the 12~(th) week the mitochondria of endothelia cells of aorta pectoralis of type 2 diabetic rats were well-stacked and slightly swollen.The mitochondria cristae were clear.No smooth cells penetrated into theca interna. Smooth cells of tunica media proliferated and the gap between myocardial tissues widened. The sarcomere was vague.The mitochondria of endothelia cells of aorta pectoralis of type 2 DM+TLR were well-stacked and slightly swollen.The mitochondria cristae were clear. No smooth cells penetrated into theca interna.The gap between myocardial tissues was normal and the sarcomere was clear.3) Expression of iNOS mRNA:The expression of iNOS mRNA of myocardial cells and aorta of obese rats were not different from that of normal controls.The expression of iNOS mRNA of myocardial cells and aorta of type 2 diabetic rats were significantly lower than that of normal controls.The expression of iNOS mRNA of myocardial cells and aorta of type 2 DM+TLR were not different than that of normal controls and there was no significant difference between type 2 DM+TLR and type 2 DM+atorvastatin.4) Expression of PKCβ_2 and OPN:The expression of PKCβ_2 of myocardial cells of obese rats increased compared with normal controls.The expression of PKCβ_2 of myocardial cells of obese+TLR was lower than that of obese rats.There was no significant difference between obese+TLR and obese+atorvastatin.The expression of PKCβ_2 of myocardial cells of type 2 diabtic rats increased significantly compared with normal controls.The expression of PKCβ_2 of myocardial cells of type 2 DM+TLR was higher than that of normal controls but lower than that of type 2 diabetic rats.The expression of PKCβ_2 of myocardial cells of type 2 DM+ALA and type 2 DM+atorvastatin was higher than that of normal controls and type 2 DM+TLR but lower than that of type 2 diabetic rats.There was no significant difference between the two groups.②OPN:The OPN of obese rats increased compared with normal controls.The OPN of obese+TLR was lower than that of type 2 diabetic rats but higher than that of normal controls.There was no significant difference between obese+ALA and obese+atorvastatin.However the OPN in the above two groups was higher than that of obese+TLR.The expression of OPN of type 2 diabtic rats increased significantly compared with normal controls.The expression of OPN of type 2 DM+TLR was significantly lower than that of type 2 diabetic rats.There was no significant difference between type 2 DM+ALA and type 2 DM+atorvastatin.
Conclusions:1) As the increase of insulin level in the obese rats,the oxidative stress parameters were characterized by the decreasing of the antioxdiative parameters and the increasing of oxidative parameters.There were no obvious pathological changes of the myocardial cells and endothelial cells.The plasma OPN was higher than that of normal controls,2) The antioxidative parameters in diabetic rats continued to decrease further.The oxidative stress parameters in type 1 diabetic rats were significantly higher than those of obese or diabetic rats.The changes of serum CRP,NO and 24-hour urine proteins reflected the dysfunction of endothelia cells of type 2 diabetic rats.The pathological changes of diabetic rats further affirmed the impairment of endothelia function.The expressions of PKCβ_2 in myocardial cells and OPN in myocardial cells and aorta of type 2 diabetic rats were significant higher than those of normal controls.3) The intervention of TLR decreased the 24-hour urine proteins,CRP and oxidative stress parameters and increased the antioxidative parameters and NO.It also improved the lesions of myocardial cells and endothelial cells of rats and decreased the expression of PKCβ_2 of myocardial cells,serum OPN and expression of OPN in myocardial cells and aorta.It could be one of the mechanisms of the TLR that down-regulating the expression of OPN,enhancing the activity of iNOS and increasing the synthesis of NO by inhibition the oxidative stress, decrease of the CRP and 24-h urine proteins,inhibition of expression of PKCβ_2.
Part 1 Effects of Tongluo recipe on oxidative stress of obese and diabetic rats
To investigate the oxidative stress lesions in diabetic and obese rats and the effects of TLR,compare the effects of TLR with those of antioxidants ALA,atorvastatin and explore the possible mechanisms of TLR protective effects on endothelia cells.
The results shows:It could be one of the mechanisms of the TLR that down-regulating the oxidative stress lesions,increasing the synthesis of NO by inhibition the oxidative stress,decrease of the CRP and 24-h urine proteins.It maybe the one of the mechanisms protecting the function of endothelium.
Part 2 Ultrastructural changes of myocardium and aorta ofdiabetic rats
To observe the histological and ultrastructural changes of myocardium and aorta of obese and experimental type 2 diabetic rats and the protective effects of TLR.
The results shows:The changes of myocardial cells and endothelial cells of aorta of obese rats were not significant.The pathological changes of myocardial cells and endothelial cells of aorta of type 1 diabetic rats were more significant than those of type 2 diabetic rats.Intervention of TLR could improve the pathological changes of changes of myocardial cells and endothelial cells of aorta of type 1 and 2diabetic rats.Compared with atorvastatin there was no significant difference and TLR had protective effects on myocardial cells and endothelial cells of aorta.
Part 3 Expression of iNOS mRNA in myocardium and aorta of obese and experimental type 2 diabetic rats and intervention effects of TLR
To investigate the expression of iNOS mRNA in myocardium and aorta of obese and experimental type 2 diabetic rats and intervention effects of TLR.
The results shows:The expression of iNOS mRNA of myocardial cells and endothelial cells of aorta of obese rats did not significantly differ from that of normal controls.The expression of iNOS mRNA of myocardial cells and endothelial cells of aorta of type 2 diabetic rats was significantly lower than that of normal controls.The intervention of TLR could increase expression of iNOS mRNA of myocardial cells and endothelial cells of aorta and the synthesis of NO,thus protected the endothelia cells.This kind of effects was not significantly different from those of atorvastatin.
Part 4 Expression of protein OPN in myocardium and aorta of obese and experimental type 2 diabetic rats and the intervention effects of TLR
To investigate the expression of protein OPN in myocardium and aorta of obese and experimental type 2 diabetic rats and the intervention effects of TLR.
The results shows:TLR could decrease plasma OPN of diabetic and obese rats and expression of protein PKCβ_2 of myocardial cells of diabetic rats.The effects of TLR were not significantly different from those of atorvastatin and ALA.TLR could also decrease expression of protein OPN in myocardium and aorta of obese and experimental type 2 diabetic rats.The effects were stronger than those of atorvastation and ALA.To protect the function of endothelium.
Background and objectives:Nowadays obesity and diabetes have become the main diseases that affect human health,and diabetic complications have been the major cause leading to high morbility and mortality of cardiovascular diseases.Dysfunction of endothelial cells attributed to chronic hyperglycemia related oxidative stress is a major factor leading to diabetic macroanglopathy and microanglopathy,and obesity related chronic mild inflammation which leads to insulin resistance is the initial factors contributing to diabetic vascular complications.Osteopontin(OPN) is a multifunctional extracelluar matrix protein and also a kind of cell secretory protein,proinflammation factor and adhesion molecular.It plays a great role in mediating cell aggregation,adhesion, migration,mineralization and reconstruction of bone,immunoregulation,signal transduction and immunity to infectious diseases.Injuries,reparation and remodeling of blood vessles all could stimulate expression of OPN.Hyperglycemia could stimulate expression of OPN in smooth muscle cells.Expression of OPN is up-regulated in smooth muscle cells from diabetic rats and diabetic patients' tunica media of arteries.Oxidative stress induced by hyperglycemia could activate PKC,increase expression of OPN, down-regnlate expression of iNOS,decrease NO,thus affect endothelial functions. Recently OPN has been found to be a pre-inflammation factor.It is highly expressed in fat tissues,could mediate infiltration of macrophage into fat tissue,and is associated with the development of insulin resistance.OPN also has an important role in diabetic anglopathy[4].This study explored the possible mechanisms of Tongluo recipe's protective effects on endothelial functions by observing the pathological changes of myocardium and aorta of obese and experimental diabetic rats,measuring plasma OPN, CRP of obese and experimental diabetic rats and mRNA of iNOS and expression of OPN protein in myocardium and aorta of obese and experimental diabetic rats,so that provide new target and theoretical evidence of diabetic complications.
Materials and methods:We studied the type 1 diabetic rats,obese and experimental type 2 diabetic rats.A number of method including HE dying,electronmicroscope, enzyme-labeled immunosorbent assay,immunohistochemistry,westernblot and RT-PCR were used.The lesions caused by oxidative stress and lipotoxicity,changes of adhere factors and the pre-inflammation factor OPN and the protective effects of TLR on myocardial cells and endothelia of aorta.We also compared the effects of TLR with antioxidants including a-lipoic acid,atorvastatin to further determine the protective effects of TLR and its possible mechanisms.
Results:1) The effects of TLR on oxidative stress of obese and diabetic rats:①Plasma oxidative stress parameters:SOD,GSH,T-AOC,CAT in type 1 diabetic rats significantly reduced compared with normal controls and MDA significantly increased. SOD,GSH,T-AOC,CAT in type 1 diabetes+TLR and type 1DM+ALA increased compared with normal controls,but there were no significant difference.MDA in type 2 diabetic rats was higher than normal controls and SOD significantly reduced.SOD in type 2 diabetes +ALA,type 2 diabetes+TLR were lower than normal controls,but the difference has no significance.MDA in type 2 diabetes +ALA,type 2 diabetes+TLR was lower than DM,but higher than NC.The difference had no significance.②Serum CRP: CRP of obese rats was significantly higher than that of normal controls.CRP of obese+TLR was lower than that of obese rats and the difference was significant.There was no significant difference among obese+atorvastatin,obese+ALA and obese+TLR.CRP of type 2 diabetic rats was significantly higher than that of normal controls.There was no significant difference among type 2 DM+atorvastatin,type 2 DM +ALA and type 2 DM +TLR.CRP of the three groups was lower than that of type 2 diabetic rats;③Changes of blood lipids:TG of obese rats was higher than that of normal controls.TG of obese+TLR increased at the fourth and eighth week,but remained lower than normal controls.At the 12~(th) week it decreased significantly.TG of type 2 diabetic rats was higher than that of normal controls.TG of type 2 DM+TLR reduced from the fourth and it was lower than diabetic rats by the end of the 12~(th) week.The TG of type 2 DM remained higher than normal controls.The TG of type DM+TLR was lower than that of type 2DM+atorvastatin and it reduced significantly compared with that of type 2 DM+AL.TC:At the 4~(th) week TC of obese rats was higher than that of normal controls.TC of obese+TLR also increased at the fourth and eighth week,but remained lower than obese rats.At the 12~(th) week it decreased.TC of type 2 diabetic rats was significantly higher than that of normal controls. The peak appeared at the 4~(th) week and it began to reduce at the 8~(th) and 12~(th) week.TC of type 2 DM+TLR reduced from the fourth and it was lower than diabetic rats by the end of the 12~(th) week.However the TC of type 2 DM remained higher than normal controls.The TC of type DM+atorvastatin reduced more than that of type 2DM+TLR,and the TC of type 2 DM+ALA did not reduce so much as that of type 2 DM+atorvastatin and type 2DM+TLR.HDL:HDL of obese rats was lower than that of normal controls.HDL of obese+TLR was higher than that of obese rats.HDL of type 2 diabetic rats was significantly lower than that of normal controls.TC of type 2 DM+TLR increased significantly compared with diabetic rats,but it was lower than diabetic rats.However the HDL of type 2 DM remained higher than normal controls.There was no significant difference between type 2 DM+TLR and type 2 DM+atorvastatin but the difference between type 2 DM+TLR and type 2 DM+ALA had statistical significance.LDL:LDL of obese rats was higher than that of normal controls.LDL of obese+TLR was higher than that of normal controls but lower than that of obese rats.LDL of type 2 diabetic rats was significantly higher than that of normal controls.The LDL of type 2 DM+TLR was significantly lower than that of type 2 DM,but it was higher than normal controls Reduction of LDL in type 2 DM+TLR was less than that of type 2 DM+atorvastatin but more than type 2 DM+ALA.④iNOS:Serum iNOS of obese rats was lower than that of normal controls.The iNOS of type 2 DM+TLR was significantly higher than that of type 2 DM,but it was still lower than normal controls.There was no significant difference in iNOS between type 2 DM+TLR and type 2 DM+atorvastatin but the difference between type 2 DM+TLR and type 2 DM+ALA had statistical significance;⑤24-hour urine proteins:There was no significant difference on the 24-hour urine proteins between obese rats and normal controls and there also had no statistical difference among obese+TLR, obese+ALA and obese+atorvastatin.24-hour urine proteins of type 2 diabetic rats were significantly higher than those of normal controls.The peak appeared at the 4~(th) week and began to reduce at the 8~(th) and 12~(th) week.24-hour urine proteins of type 2 DM+TLR began to reduce from the 4~(th) week and were significantly lower than those of type 2 diabetic rats at the 8~(th) and 12~(th) week,but remained higher than those of normal controls.The reduction of type 2 DM+atorvastatin was more than that of type 2 DM +TLR,and reduction of type 2 DM +TLR was more than that of type 2 DM+ALA.2)histological changes of myocardia and aorta of diabetic rats:①HE dying:normal myocardia had the morphology of short cylinder.The nucleus was oval-shape and in the middle of the cytoplasma.Myofibrilla could be seen in the cytoplasma.The outline of cell was clear.Mitochondria of diabetic rats were swollen and some of the cristae were broken.Vacuolization could be seen in parts of the mitochondria.The lesions of type 2 DM+TLR were significantly milder than those of type 2 DM.There was no significant difference between type 2 DM+TLR and type 2 DM+atorvastatin.The normal endothelia of intima of aorta pectoralis and smooth cells of tunica media were in regular array and complete.There was no significant difference between obese rats and normal controls.At the 12~(th) week Endothelial cells of diabetic rats were in irregular array and the smooth cells of tunica media proliferated.The lesions of type 2 DM+TLR were significantly milder than those of type 2 DM.There was no significant difference between type 2 DM+ALA and type 2 DM+atorvastatin.②electronmicroscope:In NC,tochondria of myocardial cells were complete.Crista mitochondriales were in parallel array.Myofilament was seen clearly. Myocomma was in good order and intercalary disc was normal.The structures and numbers of mitochondria were normal.At the 12~(th) week myofilament of myocardial cells of type 2 diabetic rats were twisted and the mitochondria were swollen.Some of the cristae were broken.Vacuolization could be seen in parts of the mitochondria.The lesions of type 2 DM+TLR were significantly milder than those of type 2 DM.There was no significant difference between type 2 DM+TLR and type 2 DM+atorvastatin.The normal endothelial cells were thin and flat.The nucleus was fusiform..At the 12~(th) week the mitochondria of endothelia cells of aorta pectoralis of type 2 diabetic rats were well-stacked and slightly swollen.The mitochondria cristae were clear.No smooth cells penetrated into theca interna. Smooth cells of tunica media proliferated and the gap between myocardial tissues widened. The sarcomere was vague.The mitochondria of endothelia cells of aorta pectoralis of type 2 DM+TLR were well-stacked and slightly swollen.The mitochondria cristae were clear. No smooth cells penetrated into theca interna.The gap between myocardial tissues was normal and the sarcomere was clear.3) Expression of iNOS mRNA:The expression of iNOS mRNA of myocardial cells and aorta of obese rats were not different from that of normal controls.The expression of iNOS mRNA of myocardial cells and aorta of type 2 diabetic rats were significantly lower than that of normal controls.The expression of iNOS mRNA of myocardial cells and aorta of type 2 DM+TLR were not different than that of normal controls and there was no significant difference between type 2 DM+TLR and type 2 DM+atorvastatin.4) Expression of PKCβ_2 and OPN:The expression of PKCβ_2 of myocardial cells of obese rats increased compared with normal controls.The expression of PKCβ_2 of myocardial cells of obese+TLR was lower than that of obese rats.There was no significant difference between obese+TLR and obese+atorvastatin.The expression of PKCβ_2 of myocardial cells of type 2 diabtic rats increased significantly compared with normal controls.The expression of PKCβ_2 of myocardial cells of type 2 DM+TLR was higher than that of normal controls but lower than that of type 2 diabetic rats.The expression of PKCβ_2 of myocardial cells of type 2 DM+ALA and type 2 DM+atorvastatin was higher than that of normal controls and type 2 DM+TLR but lower than that of type 2 diabetic rats.There was no significant difference between the two groups.②OPN:The OPN of obese rats increased compared with normal controls.The OPN of obese+TLR was lower than that of type 2 diabetic rats but higher than that of normal controls.There was no significant difference between obese+ALA and obese+atorvastatin.However the OPN in the above two groups was higher than that of obese+TLR.The expression of OPN of type 2 diabtic rats increased significantly compared with normal controls.The expression of OPN of type 2 DM+TLR was significantly lower than that of type 2 diabetic rats.There was no significant difference between type 2 DM+ALA and type 2 DM+atorvastatin.
Conclusions:1) As the increase of insulin level in the obese rats,the oxidative stress parameters were characterized by the decreasing of the antioxdiative parameters and the increasing of oxidative parameters.There were no obvious pathological changes of the myocardial cells and endothelial cells.The plasma OPN was higher than that of normal controls,2) The antioxidative parameters in diabetic rats continued to decrease further.The oxidative stress parameters in type 1 diabetic rats were significantly higher than those of obese or diabetic rats.The changes of serum CRP,NO and 24-hour urine proteins reflected the dysfunction of endothelia cells of type 2 diabetic rats.The pathological changes of diabetic rats further affirmed the impairment of endothelia function.The expressions of PKCβ_2 in myocardial cells and OPN in myocardial cells and aorta of type 2 diabetic rats were significant higher than those of normal controls.3) The intervention of TLR decreased the 24-hour urine proteins,CRP and oxidative stress parameters and increased the antioxidative parameters and NO.It also improved the lesions of myocardial cells and endothelial cells of rats and decreased the expression of PKCβ_2 of myocardial cells,serum OPN and expression of OPN in myocardial cells and aorta.It could be one of the mechanisms of the TLR that down-regulating the expression of OPN,enhancing the activity of iNOS and increasing the synthesis of NO by inhibition the oxidative stress, decrease of the CRP and 24-h urine proteins,inhibition of expression of PKCβ_2.
Part 1 Effects of Tongluo recipe on oxidative stress of obese and diabetic rats
To investigate the oxidative stress lesions in diabetic and obese rats and the effects of TLR,compare the effects of TLR with those of antioxidants ALA,atorvastatin and explore the possible mechanisms of TLR protective effects on endothelia cells.
The results shows:It could be one of the mechanisms of the TLR that down-regulating the oxidative stress lesions,increasing the synthesis of NO by inhibition the oxidative stress,decrease of the CRP and 24-h urine proteins.It maybe the one of the mechanisms protecting the function of endothelium.
Part 2 Ultrastructural changes of myocardium and aorta ofdiabetic rats
To observe the histological and ultrastructural changes of myocardium and aorta of obese and experimental type 2 diabetic rats and the protective effects of TLR.
The results shows:The changes of myocardial cells and endothelial cells of aorta of obese rats were not significant.The pathological changes of myocardial cells and endothelial cells of aorta of type 1 diabetic rats were more significant than those of type 2 diabetic rats.Intervention of TLR could improve the pathological changes of changes of myocardial cells and endothelial cells of aorta of type 1 and 2diabetic rats.Compared with atorvastatin there was no significant difference and TLR had protective effects on myocardial cells and endothelial cells of aorta.
Part 3 Expression of iNOS mRNA in myocardium and aorta of obese and experimental type 2 diabetic rats and intervention effects of TLR
To investigate the expression of iNOS mRNA in myocardium and aorta of obese and experimental type 2 diabetic rats and intervention effects of TLR.
The results shows:The expression of iNOS mRNA of myocardial cells and endothelial cells of aorta of obese rats did not significantly differ from that of normal controls.The expression of iNOS mRNA of myocardial cells and endothelial cells of aorta of type 2 diabetic rats was significantly lower than that of normal controls.The intervention of TLR could increase expression of iNOS mRNA of myocardial cells and endothelial cells of aorta and the synthesis of NO,thus protected the endothelia cells.This kind of effects was not significantly different from those of atorvastatin.
Part 4 Expression of protein OPN in myocardium and aorta of obese and experimental type 2 diabetic rats and the intervention effects of TLR
To investigate the expression of protein OPN in myocardium and aorta of obese and experimental type 2 diabetic rats and the intervention effects of TLR.
The results shows:TLR could decrease plasma OPN of diabetic and obese rats and expression of protein PKCβ_2 of myocardial cells of diabetic rats.The effects of TLR were not significantly different from those of atorvastatin and ALA.TLR could also decrease expression of protein OPN in myocardium and aorta of obese and experimental type 2 diabetic rats.The effects were stronger than those of atorvastation and ALA.To protect the function of endothelium.
引文
1 Zimmet, P., Alberti, K. G. and Shaw, J. (2001) Global and societal implications of the diabetes epidemic. Nature (London) 414,782-787
2 Fox, C. S., Coady, S., Sorlie, P. D. et al. (2004) Trends in cardiovascular complications of diabetes. JAMA, J. Am. Med. Assoc. 292,2495-2499
3 Winer, N. and Sowers, J. R. (2004) Epidemiology of diabetes. J. Clin. Pharmacol. 44,397-405 C_ 2005 The Biochemical Society Vascular complications in diabetes mellitus: the role of endothelial dysfunction 155
4 Duby, J. J., Campbell, R. K., Setter, S. M., White, J. R. and Rasmussen, K. A. (2004) Diabetic neuropathy: an intensive review. Am. J. Health Syst. Pharm. 61,160-173
5 Goldberg, R. B. (2003) Cardiovascular disease in patients who have diabetes. Cardiol. Clin. 21, 399-413, vii
6 Kikkawa, R., Koya, D. and Haneda, M. (2003)Progression of diabetic nephropathy. Am. J. Kidney Dis.41, S19-S21
7 Porta, M. and Bandello, F. (2002) Diabetic retinopathy: a clinical update. Diabetologia 45, 1617-1634
8 Jialal, I., Devaraj, S. and Venugopal, S. K. (2004)C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 44,6-11C. 2005 The Biochemical Society Vascular complications in diabetes mellitus: the role of endothelial dysfunction 159
9 Venugopal, S. K., Devaraj, S. and Jialal, I. (2005) Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr. Opin.Nephrol. Hypertens. 14, 33-379
10 Caballero, A. E. (2003) Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes. Res. 11,1278-1289
11 De Caterina, R. (2000) Endothelial dysfunctions:common denominators in vascular disease. Curr. Opin. Lipidol. 11,9-23
12 Stehouwer, C. D., Lambert, J., Donker, A. J. and van Hinsbergh, V. W. (1997) Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc. Res. 34,55-68
13 Kawashima, S. (2004) The two faces of endothelial nitric oxide synthase in the pathophysiology of atherosclerosis. Endothelium 11, 99-107
14 McGinn, S., Saad, S., Poronnik, P. and Pollock, C. A.(2003) High glucose-mediated effects on endothelial cell proliferation occur via p38 MAP kinase. Am. J. Physiol. Endocrinol. Metab, 285, E708-E717
15 Kofler, S., Nickel, T. and Weis, M. (2005) The role of cytokines in cardiovascular diseases: focus on endothelial response to inflammation. Clin. Sci. 108,205-213
1. Caballero, A. E. (2003) Endothelial dysfunction inobesity and insulin resistance: a road to diabetes and heart disease. Obes. Res. 11,1278-1289
2. Todoric J, Loffler M, Huber J, Bilban M, Reimers M, Kadl A, Zeyda M, Waldhausl W,Stulnig TM 2006 Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia 49:2109-2119,
3. Taddei S, Virdis A. Ghiadoni L, et al. Efects of antihypertensive drugs on endothelial dysfunction: clinical implications [J]. Drugs, 2002, 62(2): 265 284.
4. Hu FB. Stampfer MJ. Is type 2 diabetes mellitns a vascular ondition[J]. Artenoacler Thmmb Vaac Biol, 2003, 23(Io): 1715-1716.
5. Xu G, Sun W, He D, Wang L, Zheng W, Nie H, Ni L, Zhang D, Li N, Zhang J 2005 Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated withjoint inflammation, not with genetic polymorphism. J Rheumatol 32:410-416
6. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques [J] .Arterioscler Thromb Vasc Biol, 2001,21(12): 1998-2003.
7. Zi G,Oparil S,Kelpke SS,et al. Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell|dependen adventitial fibroblast migration in vitro [J] .Circulation,.2002,106:854-859.
8. Choinder P, Sodhi, Saroini A, et al. Hypoxia stimulates osteopontin expression and proliferation of cultured vascular smooth muscle cells potentiation by high glucose [J] .Diabetes,2001,50(6): 1482-1490.
9. Renault MA, Jalvy S, Belloc I, et al. AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells [J] .Circ Res,2003,93(7):674-681.
10. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007 Nov;27(11):2302-9.
11. Standal T, Borset M, Sundan A 2004 Role of osteopontin in adhesion, migration, cell survival and bone remodeling.Exp Oncol 26:179-184
12.Mazzali M,Kipari T,Ophascharoensuk V,Wesson JA,Johnson R,Hughes J 2002Osteopontin--a molecule for all seasons.Qjm 95:3-13
13.Iizuka K,Murallami T,Kawaguchi H.Pure atmospheric pressure promotes an expression of osteopontin in human aortic smooth muscle cells[J].Biochem Biophys Res Commun,2001,283(2):493-498.
14.吴以岭.防治并举,建立糖尿病系统服务工程.中国中医基础医学杂志,2001,7(12):945-946
15.吴以岭,主编.络病学.北京:中国科学技术出版社.2004
1.Cines,D.B.,Pollak,E.S.,Buck,C.A.et al.(1998)Endothelial cells in physiology and in the pathophysiology of vascular disorders.Blood 91,3527-3561
2.Quyyumi,A.A.(1998) Endothelial function in health and disease:new insights into the genesis of cardiovascular disease.Am.J.Med.105,32S-39S
3.Kawashima,S.(2004) The two faces of endothelial nitric oxide synthase in the athophysiology of atherosclerosis.Endothelium 11,99-107
4.周迎生。高妍。李斌,等.高脂喂养联合链脲佐菌素注射的糖尿病大鼠模型特征.中国实验动物学报,2005;13(3):154-158.
5.Karamitsos TD,Karvotmis HI,Dalamanga EGret al.Early diastolic inpairment of diabetic heart the significance of right ventricle.Int J Cardiol,2007,114:218-223.
6.Asbun J,Villarreal FJ.The pathogenesis of myocardial fibrosis in the setting of diabetic cardimyopathy.Am Coll Cardio 2006,47:693-700.
7.钟明,张运,苗雅等.缬沙坦逆转糖尿病心肌病大鼠心肌间质纤维化的作用[J].中华医学杂志,2006,(04):232-236.
8.吴以岭,主编.络病学.北京:中国科学技术出版社.2004
9.Gerstein,H.C.(2002) Epidemiologic analyses of risk factors,risk indicators,risk markers,and causal factors.The example of albuminuria and the risk of cardiovascular disease in diabetes.Endocrinol.Metab.Clin.North Am.31,537-551
10.Verrotti,A.,Greco,R.,Basciani,F.,Morgese,G.and Chiarelli,F.(2003) von Willebrand factor and its propeptide in children with diabetes.Relation between endothelial dysfunction and microalbuminuria.Pediatr.Res.53,382-386
11.Rajamannan NM,Subramaniam M,Springett M,etal.Atorvasta.tin inhibits hypercholestemlemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve[J].Circulation,2002,105:2660-5.
12.Bacon,P.A.(2005) Endothelial cell dysfunction in systemic vasculitis:new developments and therapeutic prospects.Curr.Opin.Rheumatol.17,49-55
13.Henry,R.M.,Ferreira,I.,Kostense,P.J.et al.(2004) Type 2 diabetes is associated with impaired endotheliumdependent,flow-mediated dilation,but impaired glucose
14.Steinberg,H.O.and Baron,A.D.(2002) Vascular function,insulin resistance and fatty acids.Diabetologia 45,623-634
1 Caballero,A.E.(2003) Endothelial dysfunction in obesity and insulin resistance:a road to diabetes and heart disease.Obes.Res.11,1278-1289
2 Rabelink,Ton J,Luscher,et al.Endothelial Nitric Oxide Synthase:Host Defense Enzyme of the Endothelium?[J].Arteriosclerosis,Thrombosis & Vascular Biology,2006,26(2):267-271.
3 Zoccali,Carmine.Asymmetric Dimethylarginine(ADMA):a Cardiovascular and Renal Risk Factor on the Move[J].Journal of Hypertension,2006,24(4):611-619.
4 Du,X.L.,Edelstein,D.,Dimmeler,S.,Ju,Q.,Sui,C.and Brownlee,M.(2001)Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site.J.Clin.Invest.108,1341-1348
5 Amore,A.,Cirina,P.,Conti,G.et al.(2004) Amadoriconfigurated albumin induces nitric oxide-dependent apoptosis of endothelial cells:a possible mechanism of diabetic vasculopathy.Nephrol.,Dial.,Transplant.19,53-60
6 Guzik,T.J.,Mussa,S.,Gastaldi,D.et al.(2002) Mechanisms of increased vascular superoxide production in human diabetes mellitus:role of NAD(P)H oxidase and endothelial nitric oxide synthase.Circulation 105,1656-1662
7 DayoubHayan,Achan Vinod,Adimoolam,et al.Asymmetric Dimethylarginine,Derangements of the Endothelial Nitric Oxide Synthase Pathway and Cardiovascular Diseases[R].Seminars in Thrombosis & Hemostasis,2000,26(5):539-545.
8 吴以岭,主编.络病学.北京:中国科学技术出版社.2004
9 吴以岭.防治并举,建立糖尿病系统服务工程.中国中医基础医学杂志,2001,7(12):945-946
1 Tickerhoof MM, Farrell PA, Korzick DH: Alterations in rat coronary vasoreactivity and vascular protein kinaseCisoforms in Type 1 diabetes.Am J Physiol Heart Circ Physiol 285: H2694-H2703, 2003
2 Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques [ J] .Arterioscler Thromb Vasc Biol, 2001,21(12): 1998-2003.
3 O'Regan A, Berman JS.Osteopontin:A key cytokine in cell|mediated and granulomatous inflammation [J] .Int J EXP Pathol, 2000,81:373-390.
4 Iizuka K, Murallami T, Kawaguchi H. Pure atmospheric pressure promotes an expression of osteopontin in human aortic smooth muscle cells [J] .Biochem Biophys Res Commun, 2001,283(2):493-498.
5 Choinder P, Sodhi, Saroini A, et al. Hypoxia stimulates osteopontin expression and proliferation of cultured vascular smooth muscle cells potentiation by high glucose
6 Zi G, Oparil S,Kelpke SS,et al. Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell|dependen adventitial fibroblast migration in vitro [J] .Circulation,.2002,106:854-859.
7 Renault MA, Jalvy S, Belloc I, et al. AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells [J] .Circ Res,2003,93(7):674-681.
8 Mine S, TabataT, Wada Y, et 81. Oxidized low density lipoprotein·indueed LFA. 1. dependent adhesion and transendohtelial migration of monocytes via the protein kinase C pathway. Atherosclerosis, 2002, 16o: 281-288.
9 Mukhe6ee S, Coaxum SD, Maleque M, et 81. Efects ofoxidized 1OW density lipoprotein on nitrie oxide synthetase and protein kinase C activities in bovine endo(?)eli81 eens. Cell Mol Biol. 2001. 47: 1051. 1058.
10 Dempsey EC, Newton AC, Mochly-Rosen D, Fields AP, Reyland ME,Insel PA, Messing RO: Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol 279:L429-L438,2000
11 Park JY, Takahara N, Gabriele A, Chou E, Naruse K, Suzuma K,Yamauchi T, Ha SW, Meier M, Rhodes CJ, King GL: induction of endothelin-1 expression by glucose: An effect of protein kinase C activation.Diabetes 49:1239-1248,2000
1. Caballero, A. E. (2003) Endothelial dysfunction inobesity and insulin resistance: a road to diabetes and heart disease. Obes. Res. 11,1278-1289
2. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques [J] .Arterioscler Thromb Vasc Biol, 2001,21(12): 1998-2003.
3. Lim}Is, Chong AYo Freestone B, et a / . The efect of multi-factorial in-tervention oil plasma von Willebrand factor, soluble E-adectin and tissue factOr in diabetes mellitus: implications for atheroaclemtic vascular disease[J]. Diabet Med. 2005, 22(3): 249-255.
4. Taddei S, Virdis A. Ghiadoni L, et al. Efects of antihypertensive drugs on endothelial dysfunction: clinical implications [J]. Drugs, 2002, 62(2): 265 284.
5. Hu FB. Stampfer MJ. Is type 2 diabetes mellitns a vascular condition?[J]. Artenoacler Thmmb Vaac Biol, 2003, 23(Io): 1715-1716.
6. Xu G, Sun W, He D, Wang L, Zheng W, Nie H, Ni L, Zhang D, Li N, Zhang J 2005 Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated withjoint inflammation, not with genetic polymorphism. J Rheumatol 32:410-416
7. Todoric J, Loffler M, Huber J, Bilban M, Reimers M, Kadi A, Zeyda M, Waldhausl W,Stulnig TM 2006 Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia 49:2109-2119,
8. Zi G,Oparil S,Kelpke SS,et al. Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell|dependen adventitial fibroblast migration in vitro [J] .Circulation,.2002,106:854-859.
9. Choinder P, Sodhi, Saroini A, et al. Hypoxia stimulates osteopontin expression and proliferation of cultured vascular smooth muscle cells potentiation by high glucose [J] .Diabetes,2001,50(6): 1482-1490.
10. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007 Nov;27(11):2302-9.
11. Standal T, Borset M, Sundan A 2004 Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26:179-184
12. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J 2002 Osteopontin-a molecule for all seasons. Qjm 95:3-13
13. Iizuka K, Murallami T, Kawaguchi H. Pure atmospheric pressure promotes an expression of osteopontin in human aortic smooth muscle cells [ J] .Biochem Biophys Res Commun, 2001,283(2):493-498.
14. Renault MA, Jalvy S, Belloc I, et al. AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells [J] .Circ Res,2003,93(7):674-681.
15. Chaulet H, Desgranges C, Renault MA,et al. Extracellular nucleotides induce arterial smooth muscle cell migraion via osteopontin [J] .Circ Res,2001,89(9):772-778.
16. Chiba S, Okamoto H, Kon S, et al. Development of atherosclerosis in osteopontin transgenic mice [J] .Heart Vessels, 2002,16(3):111-117.
17. Rangaswami H, Bulbule A, Kundu GC 2006 Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16:79-87
18. Isoda K, Nishikawa K, Kamezawa Y,et al. Osteopontin plays an improtant role in the development of medial thickening and neointimal formation [J] .Circ Res, 2002,91(1):77-82.
19. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B 2006 Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17:4-12.
20. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. 2003 Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808
21. Isoda K, Kamezawa Y, Ayaori M, Kusuhara M, Tada N, Ohsuzu F 2003 Osteopontin transgenic mice fed a high-cholesterol diet develop early fatty-streak lesions. Circulation 107:679-681
22. Matsui Y, Jia N, Okamoto H, Kon S, Onozuka H, Akino M, Liu L, Morimoto J, Rittling SR, Denhardt D, Kitabatake A, Uede T 2004 Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 43:1195-1201.
23. Quilliot D, Alla F, Bohme P, Bruntz JF, Hammadi M, Dousset B, Ziegler O, Zannad F 2005 Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance. Int J Obes (Lond) 29:1321-1328
24. McGill HC, Jr., McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE,Strong JP 2002 Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 105:2712-2718
25. Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, Whitington PF 2004 Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 287:G1035-1043.
26. Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, Heywood EB, Jones KL,Kawamori R, Cassis LA, Tschop MH, Bruemmer D 2007 Osteopontin mediates obesityinduced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest.
27. Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol D, Coussieu C,Basdevant A, Hen AB, Bedossa P, Guerre-Millo M, Clement K 2006 Increased infiltration of macrophages in Omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 55:1554-1561.
28. Wen JK, Han M, Zheng B,et al.Comparison of gene expression pattems and migration capability at quiescent and proliferating vascular smooth muscle cells stimulated by cytokines [J] .Life Sci,2002,70(7):799-807.
29. Shin T,Ahn M, Kim H, et al. Increased expression of osteoponin in the heart tissue of Lewis rats with experimental autoimmune myocarditis [J] J Vet Med Sci,2006,68(4):379-382.
30. Hwang SM, Lopez CA, Heck DE, Gardner CR, Laskin DL, Laskin JD, Denhardt DT 1994 Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. J Biol Chem 269:711-715
31. Sahai A., Malladi P., Melin-Aldana H., Green R.M., Whitington P.F. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am. J. Physiol. Gastrointest. Liver Physiol. 2004;287:G264-G273.
32. Chow F, Ozob E, Nikofic-PatersonD, et al. M ID I g8 in II 1Ousetype 2diabetic nephropathy: correlationwith diabetic state and progressive renal injury. Kidney Int, 2004, 65: 116-128.
33. Weber G.F., et al. Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation.. J. Leukoc. Biol. 2002;72:752-761
34. Kase S, Yokoi M, Saito W, Furudate N, Ohgami K, Kitamura M, Kitaichi N, Yoshida K,Kase M, Ohno S, Uede T 2007 Increased osteopontin levels in the vitreous of patients with diabetic retinopathy. Ophthalmic research 39:143-147
2 Fox, C. S., Coady, S., Sorlie, P. D. et al. (2004) Trends in cardiovascular complications of diabetes. JAMA, J. Am. Med. Assoc. 292,2495-2499
3 Winer, N. and Sowers, J. R. (2004) Epidemiology of diabetes. J. Clin. Pharmacol. 44,397-405 C_ 2005 The Biochemical Society Vascular complications in diabetes mellitus: the role of endothelial dysfunction 155
4 Duby, J. J., Campbell, R. K., Setter, S. M., White, J. R. and Rasmussen, K. A. (2004) Diabetic neuropathy: an intensive review. Am. J. Health Syst. Pharm. 61,160-173
5 Goldberg, R. B. (2003) Cardiovascular disease in patients who have diabetes. Cardiol. Clin. 21, 399-413, vii
6 Kikkawa, R., Koya, D. and Haneda, M. (2003)Progression of diabetic nephropathy. Am. J. Kidney Dis.41, S19-S21
7 Porta, M. and Bandello, F. (2002) Diabetic retinopathy: a clinical update. Diabetologia 45, 1617-1634
8 Jialal, I., Devaraj, S. and Venugopal, S. K. (2004)C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 44,6-11C. 2005 The Biochemical Society Vascular complications in diabetes mellitus: the role of endothelial dysfunction 159
9 Venugopal, S. K., Devaraj, S. and Jialal, I. (2005) Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr. Opin.Nephrol. Hypertens. 14, 33-379
10 Caballero, A. E. (2003) Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes. Res. 11,1278-1289
11 De Caterina, R. (2000) Endothelial dysfunctions:common denominators in vascular disease. Curr. Opin. Lipidol. 11,9-23
12 Stehouwer, C. D., Lambert, J., Donker, A. J. and van Hinsbergh, V. W. (1997) Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc. Res. 34,55-68
13 Kawashima, S. (2004) The two faces of endothelial nitric oxide synthase in the pathophysiology of atherosclerosis. Endothelium 11, 99-107
14 McGinn, S., Saad, S., Poronnik, P. and Pollock, C. A.(2003) High glucose-mediated effects on endothelial cell proliferation occur via p38 MAP kinase. Am. J. Physiol. Endocrinol. Metab, 285, E708-E717
15 Kofler, S., Nickel, T. and Weis, M. (2005) The role of cytokines in cardiovascular diseases: focus on endothelial response to inflammation. Clin. Sci. 108,205-213
1. Caballero, A. E. (2003) Endothelial dysfunction inobesity and insulin resistance: a road to diabetes and heart disease. Obes. Res. 11,1278-1289
2. Todoric J, Loffler M, Huber J, Bilban M, Reimers M, Kadl A, Zeyda M, Waldhausl W,Stulnig TM 2006 Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia 49:2109-2119,
3. Taddei S, Virdis A. Ghiadoni L, et al. Efects of antihypertensive drugs on endothelial dysfunction: clinical implications [J]. Drugs, 2002, 62(2): 265 284.
4. Hu FB. Stampfer MJ. Is type 2 diabetes mellitns a vascular ondition[J]. Artenoacler Thmmb Vaac Biol, 2003, 23(Io): 1715-1716.
5. Xu G, Sun W, He D, Wang L, Zheng W, Nie H, Ni L, Zhang D, Li N, Zhang J 2005 Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated withjoint inflammation, not with genetic polymorphism. J Rheumatol 32:410-416
6. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques [J] .Arterioscler Thromb Vasc Biol, 2001,21(12): 1998-2003.
7. Zi G,Oparil S,Kelpke SS,et al. Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell|dependen adventitial fibroblast migration in vitro [J] .Circulation,.2002,106:854-859.
8. Choinder P, Sodhi, Saroini A, et al. Hypoxia stimulates osteopontin expression and proliferation of cultured vascular smooth muscle cells potentiation by high glucose [J] .Diabetes,2001,50(6): 1482-1490.
9. Renault MA, Jalvy S, Belloc I, et al. AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells [J] .Circ Res,2003,93(7):674-681.
10. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007 Nov;27(11):2302-9.
11. Standal T, Borset M, Sundan A 2004 Role of osteopontin in adhesion, migration, cell survival and bone remodeling.Exp Oncol 26:179-184
12.Mazzali M,Kipari T,Ophascharoensuk V,Wesson JA,Johnson R,Hughes J 2002Osteopontin--a molecule for all seasons.Qjm 95:3-13
13.Iizuka K,Murallami T,Kawaguchi H.Pure atmospheric pressure promotes an expression of osteopontin in human aortic smooth muscle cells[J].Biochem Biophys Res Commun,2001,283(2):493-498.
14.吴以岭.防治并举,建立糖尿病系统服务工程.中国中医基础医学杂志,2001,7(12):945-946
15.吴以岭,主编.络病学.北京:中国科学技术出版社.2004
1.Cines,D.B.,Pollak,E.S.,Buck,C.A.et al.(1998)Endothelial cells in physiology and in the pathophysiology of vascular disorders.Blood 91,3527-3561
2.Quyyumi,A.A.(1998) Endothelial function in health and disease:new insights into the genesis of cardiovascular disease.Am.J.Med.105,32S-39S
3.Kawashima,S.(2004) The two faces of endothelial nitric oxide synthase in the athophysiology of atherosclerosis.Endothelium 11,99-107
4.周迎生。高妍。李斌,等.高脂喂养联合链脲佐菌素注射的糖尿病大鼠模型特征.中国实验动物学报,2005;13(3):154-158.
5.Karamitsos TD,Karvotmis HI,Dalamanga EGret al.Early diastolic inpairment of diabetic heart the significance of right ventricle.Int J Cardiol,2007,114:218-223.
6.Asbun J,Villarreal FJ.The pathogenesis of myocardial fibrosis in the setting of diabetic cardimyopathy.Am Coll Cardio 2006,47:693-700.
7.钟明,张运,苗雅等.缬沙坦逆转糖尿病心肌病大鼠心肌间质纤维化的作用[J].中华医学杂志,2006,(04):232-236.
8.吴以岭,主编.络病学.北京:中国科学技术出版社.2004
9.Gerstein,H.C.(2002) Epidemiologic analyses of risk factors,risk indicators,risk markers,and causal factors.The example of albuminuria and the risk of cardiovascular disease in diabetes.Endocrinol.Metab.Clin.North Am.31,537-551
10.Verrotti,A.,Greco,R.,Basciani,F.,Morgese,G.and Chiarelli,F.(2003) von Willebrand factor and its propeptide in children with diabetes.Relation between endothelial dysfunction and microalbuminuria.Pediatr.Res.53,382-386
11.Rajamannan NM,Subramaniam M,Springett M,etal.Atorvasta.tin inhibits hypercholestemlemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve[J].Circulation,2002,105:2660-5.
12.Bacon,P.A.(2005) Endothelial cell dysfunction in systemic vasculitis:new developments and therapeutic prospects.Curr.Opin.Rheumatol.17,49-55
13.Henry,R.M.,Ferreira,I.,Kostense,P.J.et al.(2004) Type 2 diabetes is associated with impaired endotheliumdependent,flow-mediated dilation,but impaired glucose
14.Steinberg,H.O.and Baron,A.D.(2002) Vascular function,insulin resistance and fatty acids.Diabetologia 45,623-634
1 Caballero,A.E.(2003) Endothelial dysfunction in obesity and insulin resistance:a road to diabetes and heart disease.Obes.Res.11,1278-1289
2 Rabelink,Ton J,Luscher,et al.Endothelial Nitric Oxide Synthase:Host Defense Enzyme of the Endothelium?[J].Arteriosclerosis,Thrombosis & Vascular Biology,2006,26(2):267-271.
3 Zoccali,Carmine.Asymmetric Dimethylarginine(ADMA):a Cardiovascular and Renal Risk Factor on the Move[J].Journal of Hypertension,2006,24(4):611-619.
4 Du,X.L.,Edelstein,D.,Dimmeler,S.,Ju,Q.,Sui,C.and Brownlee,M.(2001)Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site.J.Clin.Invest.108,1341-1348
5 Amore,A.,Cirina,P.,Conti,G.et al.(2004) Amadoriconfigurated albumin induces nitric oxide-dependent apoptosis of endothelial cells:a possible mechanism of diabetic vasculopathy.Nephrol.,Dial.,Transplant.19,53-60
6 Guzik,T.J.,Mussa,S.,Gastaldi,D.et al.(2002) Mechanisms of increased vascular superoxide production in human diabetes mellitus:role of NAD(P)H oxidase and endothelial nitric oxide synthase.Circulation 105,1656-1662
7 DayoubHayan,Achan Vinod,Adimoolam,et al.Asymmetric Dimethylarginine,Derangements of the Endothelial Nitric Oxide Synthase Pathway and Cardiovascular Diseases[R].Seminars in Thrombosis & Hemostasis,2000,26(5):539-545.
8 吴以岭,主编.络病学.北京:中国科学技术出版社.2004
9 吴以岭.防治并举,建立糖尿病系统服务工程.中国中医基础医学杂志,2001,7(12):945-946
1 Tickerhoof MM, Farrell PA, Korzick DH: Alterations in rat coronary vasoreactivity and vascular protein kinaseCisoforms in Type 1 diabetes.Am J Physiol Heart Circ Physiol 285: H2694-H2703, 2003
2 Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques [ J] .Arterioscler Thromb Vasc Biol, 2001,21(12): 1998-2003.
3 O'Regan A, Berman JS.Osteopontin:A key cytokine in cell|mediated and granulomatous inflammation [J] .Int J EXP Pathol, 2000,81:373-390.
4 Iizuka K, Murallami T, Kawaguchi H. Pure atmospheric pressure promotes an expression of osteopontin in human aortic smooth muscle cells [J] .Biochem Biophys Res Commun, 2001,283(2):493-498.
5 Choinder P, Sodhi, Saroini A, et al. Hypoxia stimulates osteopontin expression and proliferation of cultured vascular smooth muscle cells potentiation by high glucose
6 Zi G, Oparil S,Kelpke SS,et al. Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell|dependen adventitial fibroblast migration in vitro [J] .Circulation,.2002,106:854-859.
7 Renault MA, Jalvy S, Belloc I, et al. AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells [J] .Circ Res,2003,93(7):674-681.
8 Mine S, TabataT, Wada Y, et 81. Oxidized low density lipoprotein·indueed LFA. 1. dependent adhesion and transendohtelial migration of monocytes via the protein kinase C pathway. Atherosclerosis, 2002, 16o: 281-288.
9 Mukhe6ee S, Coaxum SD, Maleque M, et 81. Efects ofoxidized 1OW density lipoprotein on nitrie oxide synthetase and protein kinase C activities in bovine endo(?)eli81 eens. Cell Mol Biol. 2001. 47: 1051. 1058.
10 Dempsey EC, Newton AC, Mochly-Rosen D, Fields AP, Reyland ME,Insel PA, Messing RO: Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol 279:L429-L438,2000
11 Park JY, Takahara N, Gabriele A, Chou E, Naruse K, Suzuma K,Yamauchi T, Ha SW, Meier M, Rhodes CJ, King GL: induction of endothelin-1 expression by glucose: An effect of protein kinase C activation.Diabetes 49:1239-1248,2000
1. Caballero, A. E. (2003) Endothelial dysfunction inobesity and insulin resistance: a road to diabetes and heart disease. Obes. Res. 11,1278-1289
2. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques [J] .Arterioscler Thromb Vasc Biol, 2001,21(12): 1998-2003.
3. Lim}Is, Chong AYo Freestone B, et a / . The efect of multi-factorial in-tervention oil plasma von Willebrand factor, soluble E-adectin and tissue factOr in diabetes mellitus: implications for atheroaclemtic vascular disease[J]. Diabet Med. 2005, 22(3): 249-255.
4. Taddei S, Virdis A. Ghiadoni L, et al. Efects of antihypertensive drugs on endothelial dysfunction: clinical implications [J]. Drugs, 2002, 62(2): 265 284.
5. Hu FB. Stampfer MJ. Is type 2 diabetes mellitns a vascular condition?[J]. Artenoacler Thmmb Vaac Biol, 2003, 23(Io): 1715-1716.
6. Xu G, Sun W, He D, Wang L, Zheng W, Nie H, Ni L, Zhang D, Li N, Zhang J 2005 Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated withjoint inflammation, not with genetic polymorphism. J Rheumatol 32:410-416
7. Todoric J, Loffler M, Huber J, Bilban M, Reimers M, Kadi A, Zeyda M, Waldhausl W,Stulnig TM 2006 Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia 49:2109-2119,
8. Zi G,Oparil S,Kelpke SS,et al. Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell|dependen adventitial fibroblast migration in vitro [J] .Circulation,.2002,106:854-859.
9. Choinder P, Sodhi, Saroini A, et al. Hypoxia stimulates osteopontin expression and proliferation of cultured vascular smooth muscle cells potentiation by high glucose [J] .Diabetes,2001,50(6): 1482-1490.
10. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007 Nov;27(11):2302-9.
11. Standal T, Borset M, Sundan A 2004 Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26:179-184
12. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J 2002 Osteopontin-a molecule for all seasons. Qjm 95:3-13
13. Iizuka K, Murallami T, Kawaguchi H. Pure atmospheric pressure promotes an expression of osteopontin in human aortic smooth muscle cells [ J] .Biochem Biophys Res Commun, 2001,283(2):493-498.
14. Renault MA, Jalvy S, Belloc I, et al. AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells [J] .Circ Res,2003,93(7):674-681.
15. Chaulet H, Desgranges C, Renault MA,et al. Extracellular nucleotides induce arterial smooth muscle cell migraion via osteopontin [J] .Circ Res,2001,89(9):772-778.
16. Chiba S, Okamoto H, Kon S, et al. Development of atherosclerosis in osteopontin transgenic mice [J] .Heart Vessels, 2002,16(3):111-117.
17. Rangaswami H, Bulbule A, Kundu GC 2006 Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16:79-87
18. Isoda K, Nishikawa K, Kamezawa Y,et al. Osteopontin plays an improtant role in the development of medial thickening and neointimal formation [J] .Circ Res, 2002,91(1):77-82.
19. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B 2006 Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17:4-12.
20. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. 2003 Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808
21. Isoda K, Kamezawa Y, Ayaori M, Kusuhara M, Tada N, Ohsuzu F 2003 Osteopontin transgenic mice fed a high-cholesterol diet develop early fatty-streak lesions. Circulation 107:679-681
22. Matsui Y, Jia N, Okamoto H, Kon S, Onozuka H, Akino M, Liu L, Morimoto J, Rittling SR, Denhardt D, Kitabatake A, Uede T 2004 Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 43:1195-1201.
23. Quilliot D, Alla F, Bohme P, Bruntz JF, Hammadi M, Dousset B, Ziegler O, Zannad F 2005 Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance. Int J Obes (Lond) 29:1321-1328
24. McGill HC, Jr., McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE,Strong JP 2002 Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 105:2712-2718
25. Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, Whitington PF 2004 Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 287:G1035-1043.
26. Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, Heywood EB, Jones KL,Kawamori R, Cassis LA, Tschop MH, Bruemmer D 2007 Osteopontin mediates obesityinduced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest.
27. Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol D, Coussieu C,Basdevant A, Hen AB, Bedossa P, Guerre-Millo M, Clement K 2006 Increased infiltration of macrophages in Omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 55:1554-1561.
28. Wen JK, Han M, Zheng B,et al.Comparison of gene expression pattems and migration capability at quiescent and proliferating vascular smooth muscle cells stimulated by cytokines [J] .Life Sci,2002,70(7):799-807.
29. Shin T,Ahn M, Kim H, et al. Increased expression of osteoponin in the heart tissue of Lewis rats with experimental autoimmune myocarditis [J] J Vet Med Sci,2006,68(4):379-382.
30. Hwang SM, Lopez CA, Heck DE, Gardner CR, Laskin DL, Laskin JD, Denhardt DT 1994 Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. J Biol Chem 269:711-715
31. Sahai A., Malladi P., Melin-Aldana H., Green R.M., Whitington P.F. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am. J. Physiol. Gastrointest. Liver Physiol. 2004;287:G264-G273.
32. Chow F, Ozob E, Nikofic-PatersonD, et al. M ID I g8 in II 1Ousetype 2diabetic nephropathy: correlationwith diabetic state and progressive renal injury. Kidney Int, 2004, 65: 116-128.
33. Weber G.F., et al. Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation.. J. Leukoc. Biol. 2002;72:752-761
34. Kase S, Yokoi M, Saito W, Furudate N, Ohgami K, Kitamura M, Kitaichi N, Yoshida K,Kase M, Ohno S, Uede T 2007 Increased osteopontin levels in the vitreous of patients with diabetic retinopathy. Ophthalmic research 39:143-147